PMAM
JBIO icon

Penn Mutual Asset Management’s Jade Biosciences JBIO Stock Holding History

Penn Mutual Asset Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-499
Closed -$320K – 55
2022
Q1 		$320K Buy
+499
New +$194K 0.37% 43

Other funds holding JBIO

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

Penn Mutual Asset Management's JBIO Position: Q2 2022 in Review

Penn Mutual Asset Management sold out of Jade Biosciences (JBIO) in Q2 2022, closing a stake of 499 shares — an estimated $320K sold.

Penn Mutual Asset Management first reported a position in JBIO in Q1 2022 and held it in 1 quarter. The position peaked at $320K in Q1 2022. 49 funds tracked by Wall St. Rank hold JBIO as of Q2 2022.

  • Penn Mutual Asset Management reported no remaining Jade Biosciences position as of Q2 2022 after selling out during the quarter.
  • Penn Mutual Asset Management sold 499 Jade Biosciences shares in Q2 2022, an estimated $320K.
  • Penn Mutual Asset Management first reported a position in Jade Biosciences in Q1 2022 and held it in 1 quarter.
  • Penn Mutual Asset Management's Jade Biosciences position peaked at $320K in Q1 2022.
  • 49 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2022.

Based on Penn Mutual Asset Management's 13F filing for Q2 2022, filed 11 Aug 2022.